Moderna’s (MRNA) forward visibility is starting to firm up and its Covid-19 revenue projections disappoint, but realistic in our view, notes Hartaj Singh. He discusses the state of the biotech market as MRNA shares hit a 3-year low last week. He talks about how MRNA’s spending, and margin pressure are still and issue. He also goes over Vertex Pharmaceuticals (VRTX) which is at a new 52-week high. He then looks at Regeneron (REGN) whose shares are up 15% year-to-date. Tune in to find out more about the stock market today.
Market On Close
06 Nov 2023
SHARE
Morning Trade Live
14 Mar 2024
Morning Trade Live
27 Mar 2024
Trading 360
30 Jan 2024
Market On Close
21 Feb 2024
Morning Trade Live
27 Mar 2024
Market On Close
10 Apr 2024
Current show
Mon—Fri at 10:00 am — 11:00 am
Trading 360